Why does vaccine evaluation still take longer than candidate creation?

Question

Accepted Answer

Vaccine Evaluation Remains Lengthy Despite Rapid Candidate Creation

Despite advancements in technology allowing for the creation of candidate vaccines within weeks, the evaluation process for human use still requires a significant amount of time. This extended timeline is primarily due to the rigorous testing phases mandated to ensure both efficacy and safety before a vaccine can be registered and made available to the public. The journey from initial pre-clinical studies to widespread use typically spans an average of ten years.
Pre-Clinical and Clinical Trial Phases

Before any candidate vaccine can be administered to humans, it must first undergo extensive testing in animal studies. Following successful animal trials, the vaccine progresses to human clinical trials, which are divided into three distinct phases. Phase 1 trials focus on assessing the vaccine's safety in a small group of healthy volunteers, while Phase 2 trials expand this evaluation to a larger cohort to determine optimal dosage and further assess safety and immunogenicity. Phase 3 trials involve a much larger and diverse population to confirm the vaccine's efficacy and monitor for any adverse reactions on a broad scale.
Regulatory Approval and Registration

Once a vaccine has successfully navigated through all phases of clinical trials, demonstrating both safety and effectiveness, it must then undergo a stringent review process by regulatory bodies. These agencies, such as the Food and Drug Administration (FDA) in the United States or the European Medicines Agency (EMA) in Europe, meticulously examine all the data collected from the trials. Only after this comprehensive review and approval is the vaccine granted registration, permitting its use in the general population.
Historical Context and Technological Advancements

While the development of candidate vaccines has been significantly accelerated by modern technologies, enabling their creation in a matter of weeks rather than years, this speed does not alter the fundamental requirements for rigorous safety and efficacy testing. For instance, the rapid sequencing of the novel coronavirus genome in January 2020, completed within a month of the first reported case, contrasted sharply with the over six months it took to sequence the SARS coronavirus. However, even with such swift initial progress, the subsequent evaluation stages remain critical and time-consuming.
The Risk of Mutation and Efficacy Challenges

A persistent concern in vaccine development, particularly for RNA viruses like the novel coronavirus, is the potential for mutation. While coronaviruses possess a molecular proofreading system that can reduce their mutation rate compared to viruses like influenza, mutations can still occur. If such mutations affect key antigens, like the spike protein crucial for generating neutralising antibodies, the efficacy of a developed vaccine could be compromised, necessitating ongoing monitoring and potential updates.

Reading history

Hide →

This history is cleared when the page is closed.

Why does vaccine evaluation still take longer than candidate creation?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends